ErbB Receptors
Medicine & Life Sciences
100%
Adenocarcinoma of Lung
Medicine & Life Sciences
93%
Pneumonia
Medicine & Life Sciences
53%
Toll-Like Receptor 2
Medicine & Life Sciences
52%
SS-A antibodies
Medicine & Life Sciences
48%
Tissue Inhibitor of Metalloproteinase-3
Medicine & Life Sciences
48%
lipoteichoic acid
Medicine & Life Sciences
47%
Mutation
Medicine & Life Sciences
42%
Chen, W. L. ,
Lee, K. L. ,
Lai, K. S. ,
Tsai, J. H. ,
Hsiao, S. H. &
Chung, C. L. ,
2月 2023 ,
於: International journal of molecular sciences. 24 ,
3 , 2846.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Intercellular Signaling Peptides and Proteins
100%
Toll-Like Receptor 2
83%
Pleural Effusion
69%
Vascular Endothelial Growth Factor A
56%
tuberculosis
32%
Lee, K. L. ,
Lai, T. C. ,
Wang, Y. C. ,
Shih, P. C. ,
Yang, Y. C. ,
Tsao, T. C. Y. ,
Liu, T. C. ,
Wen, Y. C. ,
Chang, L. C. ,
Yang, S. F. &
Chien, M. H. ,
3月 2021 ,
於: Genes. 12 ,
3 , 427.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Interleukin-17
100%
Taiwan
93%
ErbB Receptors
89%
Non-Small Cell Lung Carcinoma
84%
Adenocarcinoma of Lung
67%
Chang, J. H. ,
Lai, T. C. ,
Yang, P. J. ,
Shih, P. C. ,
Yang, Y. C. ,
Lee, K. L. ,
Liu, T. C. ,
Chang-Yao Tsao, T. ,
Yang, S. F. &
Chien, M. H. ,
11月 1 2020 ,
於: International journal of molecular sciences. 21 ,
21 ,
p. 1-13 13 p. , 8023.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Metalloproteases
100%
Genetic Polymorphism
83%
Epidermal Growth Factor
80%
Tissue Inhibitor of Metalloproteinase-3
77%
polymorphism
67%
Lee, H. L. ,
Chiou, J. F. ,
Wang, P. Y. ,
Lu, L. S. ,
Shen, C. N. ,
Hsu, H. L. ,
Burnouf, T. ,
Ting, L. L. ,
Chou, P. C. ,
Chung, C. L. ,
Lee, K. L. ,
Shiah, H. S. ,
Liu, Y. L. &
Chen, Y. J. ,
11月 2020 ,
於: Cancers. 12 ,
11 ,
p. 1-17 17 p. , 3394.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Circulating Neoplastic Cells
100%
Small Cell Lung Carcinoma
89%
Pharmaceutical Preparations
33%
Cadherins
20%
Fluorescent Antibody Technique
17%
Su, I. C. ,
Lee, K. L. ,
Liu, H. Y. ,
Chuang, H. C. ,
Chen, L. Y. &
Lee, Y. J. ,
4月 1 2019 ,
於: Journal of Microbiology, Immunology and Infection. 52 ,
2 ,
p. 365-366 2 p. 研究成果: 雜誌貢獻 › 快報 › 同行評審
Coinfection
100%
Pseudomonas aeruginosa
95%
Human Influenza
94%
Pneumonia
83%
Fatal Outcome
60%